New Immunotherapy Option for Treating Metastatic Lung Cancer
The FDA expanded the use of an immunotherapy to include the treatment of certain patients with lung cancer.
Progress Against Cancer
The FDA expanded the use of an immunotherapy to include the treatment of certain patients with lung cancer.
The FDA expanded the use of an immunotherapy to include the treatment of certain patients with head and neck cancer.
The FDA approved a liquid biopsy – a test that uses a blood sample – to identify patients with metastatic non-small cell lung cancer.
The May 2016 approval of atezolizumab provided the first new treatment in more than 30 years for patients with the most common type of bladder cancer.
The FDA expanded the use of an immunotherapeutic to include certain patients with Hodgkin lymphoma. Learn more about this approval.
The FDA added lenvatinib to the armamentarium for oncologists treating certain patients with renal cell carcinoma.
The FDA approved a targeted therapeutic to treat patients with metastatic squamous non-small cell lung cancer.
The FDA approved cabozantinib for treating certain patients with the most common form of kidney cancer diagnosed in U.S. adults—renal cell carcinoma.
The FDA approved a new colorectal cancer screening test that uses blood samples to detect tumors.
The FDA approved a treatment for certain patients with chronic lymphocytic leukemia (CLL).
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More